17.16
+15.79(+1152.55%)
Currency In USD
| Previous Close | 1.37 |
| Open | 1.38 |
| Day High | 17.16 |
| Day Low | 1.36 |
| 52-Week High | 23.28 |
| 52-Week Low | 1.36 |
| Volume | 457,262 |
| Average Volume | 18,002 |
| Market Cap | 718.82M |
| PE | -2.23 |
| EPS | -7.68 |
| Moving Average 50 Days | 15.75 |
| Moving Average 200 Days | 17.08 |
| Change | 15.79 |
If you invested $1000 in Ikena Oncology, Inc. (IKNA) since IPO date, it would be worth $536.25 as of August 28, 2025 at a share price of $17.16. Whereas If you bought $1000 worth of Ikena Oncology, Inc. (IKNA) shares 3 years ago, it would be worth $3,779.74 as of August 28, 2025 at a share price of $17.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
GlobeNewswire Inc.
Jul 25, 2025 3:00 PM GMT
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
GlobeNewswire Inc.
Jul 23, 2025 1:00 PM GMT
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio (“I
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
GlobeNewswire Inc.
Jul 15, 2025 8:15 PM GMT
Combined Company to Trade on Nasdaq Under Ticker “IMA” Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) today announced the res